Related Experiment Video
Updated: Oct 3, 2025
Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
Published on: June 2, 2019
Increasing the Therapeutic Potential of Stem Cell Therapies for Critical Limb Ischemia
Hallie J Quiroz1, Samantha F Valencia2, Zhao-Jun Liu1
1Dewitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, USA.
Insights
Critical Limb Ischemia (CLI) patients often face amputation. This review explores recent advances in stem cell therapy to improve limb salvage for these "no option" cases.
Area of Science:
- Regenerative Medicine
- Vascular Biology
- Biotechnology
Background:
- Peripheral Arterial Disease (PAD) progresses to Critical Limb Ischemia (CLI), characterized by severe limb underperfusion, pain, ulcers, and gangrene.
- Many CLI patients are refractory to existing treatments, leading to amputation.
- Current stem cell therapies show modest benefits, failing to significantly reduce amputation rates.
Purpose of the Study:
- To review recent advancements in enhancing stem cell therapy for limb salvage in CLI.
- To highlight strategies for improving the therapeutic efficacy of stem cells in CLI treatment.
Main Methods:
- Review of preclinical and clinical studies on stem cell therapy for CLI.
- Analysis of novel approaches to augment stem cell function and delivery.
- Focus on angiogenic potential and therapeutic improvements.
Main Results:
- Stem cell therapy has shown promise but with limited success in reducing amputations.
- Ongoing research focuses on optimizing stem cell types, delivery methods, and combination therapies.
- Recent investigations aim to increase the angiogenic and regenerative capacity of stem cells for CLI.
Conclusions:
- Improved stem cell therapies are crucial for limb salvage in "no option" CLI patients.
- Further research is needed to translate enhanced stem cell strategies into significant clinical benefits.
- Optimizing stem cell therapy holds potential to reduce amputation rates in CLI.
Abstract:
Peripheral Arterial Disease (PAD) is a progressive, atherosclerotic disease that at its end stage, Critical Limb Ischemia (CLI), results in severely diminished limb perfusion and causes leg pain at rest, non-healing ulcers, and tissue gangrene. Many patients with CLI fail current medical and surgical therapies and thus are deemed "no option" and require limb amputation. Novel therapies to attempt limb salvage in these "no option" patients are needed. Stem cell therapy is one therapeutic angiogenic avenue that has been tested over the last 20 years. To date, clinical trials have shown promise but with only modest improvement and none demonstrated a significant decrease in amputation rates in those treated with stem cell therapy. Thus, recent investigations into improving stem cell therapy have been the focus of our laboratory and many others. This review aims to describe recent advances in increasing the therapeutic potential of stem cell therapies for CLI.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:27Peripheral Artery Disease III: Interprofessional Care